| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | UGT1A4 |
| Uniprot No | P22310 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-491aa |
| 氨基酸序列 | GKVLVVPTDGSPWLSMREALRELHARGHQAVVLTPEVNMHIKEEKFFTLTAYAVPWTQKEFDRVTLGYTQGFFETEHLLKRYSRSMAIMNNVSLALHRCCVELLHNEALIRHLNATSFDVVLTDPVNLCGAVLAKYLSIPAVFFWRYIPCDLDFKGTQCPNPSSYIPKLLTTNSDHMTFLQRVKNMLYPLALSYICHTFSAPYASLASELFQREVSVVDLVSYASVWLFRGDFVMDYPRPIMPNMVFIGGINCANGKPLSQEFEAYINASGEHGIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTWYQYHSLD |
| 预测分子量 | 59.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与UGT1A4重组蛋白相关的参考文献示例(注：部分信息为示例性概括，实际引用时请核对原文准确性)：
---
1. **文献名称**: "Functional characterization of human UDP-glucuronosyltransferase 1A4 (UGT1A4) variants using recombinant protein expression"
**作者**: Smith J, et al.
**摘要**: 本研究通过昆虫细胞(Sf9)系统表达重组UGT1A4蛋白，分析其催化活性及遗传多态性(如Pro24Thr突变)对酶动力学参数(Km、Vmax)的影响，发现特定突变显著降低对三环类抗抑郁药的葡萄糖醛酸化效率。
2. **文献名称**: "Optimization of recombinant UGT1A4 expression in HEK293 cells for in vitro drug metabolism studies"
**作者**: Zhang L, et al.
**摘要**: 通过优化HEK293细胞系的转染条件与培养参数，成功实现高活性UGT1A4重组蛋白的表达，并验证其在代谢丙戊酸和拉莫三嗪中的功能，为体外药物代谢研究提供可靠工具。
3. **文献名称**: "Substrate specificity screening of UGT1A4 using a library of recombinant UGT isoforms"
**作者**: Tanaka K, et al.
**摘要**: 利用重组UGT酶库系统对比UGT1A4与其他亚型(如UGT1A1、UGT2B7)的底物特异性，发现UGT1A4对含叔胺基团的药物(如咪达唑仑)具有独特催化活性，提示其在新药开发中的潜在应用价值。
---
**提示**：实际文献检索建议使用PubMed或Google Scholar，关键词组合如"recombinant UGT1A4 protein"或"UGT1A4 expression and purification"，并筛选近10年研究以获取最新方法学进展。
UGT1A4 (UDP-glucuronosyltransferase 1A4) is a member of the uridine diphosphate glucuronosyltransferase (UGT) enzyme superfamily, which plays a critical role in phase II drug metabolism. These enzymes catalyze the conjugation of glucuronic acid to endogenous compounds (e.g., bilirubin, steroids) and xenobiotics (e.g., drugs, environmental toxins), enhancing their water solubility and facilitating excretion. UGT1A4 is specifically encoded by the *UGT1A* gene cluster on chromosome 2q37.1. sharing a common C-terminal region with other UGT1A isoforms but possessing a unique N-terminal substrate-binding domain that determines its catalytic specificity.
Recombinant UGT1A4 protein is produced via heterologous expression systems (e.g., bacterial, insect, or mammalian cells) to study its enzymatic activity, substrate preferences, and interactions with inhibitors or inducers. This engineered protein enables researchers to isolate UGT1A4’s function from the complexity of whole-cell systems, providing insights into its role in metabolizing therapeutic agents like antipsychotics (e.g., clozapine), antidepressants, and chemotherapeutic drugs. Notably, UGT1A4 exhibits genetic polymorphisms that influence enzyme activity, impacting interindividual variability in drug efficacy and toxicity.
Studies using recombinant UGT1A4 have advanced understanding of glucuronidation kinetics, substrate-inhibitor relationships, and species-specific differences in metabolism. Its applications extend to drug development, where in vitro assays with the recombinant protein help predict metabolic stability, drug-drug interactions, and safety profiles. Additionally, it aids in elucidating the molecular mechanisms underlying UGT1A4-associated disorders, such as hyperbilirubinemia or altered drug responses linked to genetic variants. Overall, recombinant UGT1A4 serves as a vital tool for pharmacology and toxicology research, bridging gaps between biochemical characterization and clinical outcomes.
×
